Latest Biologic Stories
CAMBRIDGE, England, December 16, 2014 /PRNewswire/ -- Crescendo Biologics Limited (Crescendo) today announces a further equity investment from Astellas Venture Management
ReportsandReports.com adds latest reports on Adalimumab Industry for Global and China Markets to its store. DALLAS, Dec.
First Presentation of Phase 3 Data From Brodalumab Psoriasis Program THOUSAND OAKS, Calif. and LONDON, Dec.
The company leverages its keen understanding of protein purification to achieve the highest purification standards and product quality LONDON, Dec.
NEW YORK, Dec.
Symphogen has licensed the rights to the Selexis SUREtechnology Platform™ and SURE CHO-M Cell Line™ for the development of recombinant monoclonal antibody (MAb) mixtures for the treatment
EDISON, N.J., Dec.
DELHI, India, December 9, 2014 /PRNewswire/ -- Access to this therapy will impact 12 million people suffering from auto immune disorders like rheumatoid arthritis,
- To give a box on the ear to.